Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study

BACKGROUND: Several disease-modifying drugs have shown promising effects on cognitive impairment in multiple sclerosis (MS). Alemtuzumab, a humanized monoclonal antibody, is effective in controlling disease activity, however, has not been evaluated for its effects on cognition in detail so far. OBJE...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Neurol
Asıl Yazarlar: Riepl, Ester, Pfeuffer, Steffen, Ruck, Tobias, Lohmann, Hubertus, Wiendl, Heinz, Meuth, Sven G., Johnen, Andreas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2018
Konular:
Neuroscience
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5775967/
https://ncbi.nlm.nih.gov/pubmed/29387035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2017.00730
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller